LBA-1 Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O’Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators
N Engl J Med. 2019 Feb 21;380(8):720-728
CARDIONCOLOGY.ORG ABSTRACT:
This study reports the results from a double-blind, randomized trial involving 1080 high- risk ambulatory patients with cancer in order to determine risk for venous thromboembolism (VTE) and benefit of thromboprophylaxis.
Results indicate that treatment with rivaroxaban did not result in a significantly lower incidence of VTE or death due to VTE in the 180-day trial period of the study.
During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding.
© All rights reserved
Fonte foto: https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-hematology-ash/ash-2018/rivaroxaban-reduced-vte-and-vte-related-death-in-patients-with-cancer-results-of-the-cassini-study/